Jesse Timmermans sold $671k of RVLV
CHIEF FINANCIAL OFFICER at Revolve Group, Inc.. 21,282 shares at an average of $31.51, traded Jan 6, 2026, filed Jan 8, 2026.
Score components
- +22RoleCFO
- +20Trade size$671k at market
- +20Share of holdings soldSold 90% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -13.9%, 3m -17.9%, 6m -26.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-008019, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 6, 2026 | MOption exercise Class A Common Stock10b5-1 | +12,053 | $0.00 | $0 | 23,663 | Jan 8, 2026 |
| Jan 6, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -12,053 | $31.51 | $380k | 11,610 | Jan 8, 2026 |
| Jan 7, 2026 | MOption exercise Class A Common Stock10b5-1 | +3,880 | $0.00 | $0 | 15,490 | Jan 8, 2026 |
| Jan 7, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -3,880 | $31.50 | $122k | 11,610 | Jan 8, 2026 |
| Jan 8, 2026 | MOption exercise Class A Common Stock10b5-1 | +5,349 | $0.00 | $0 | 16,959 | Jan 8, 2026 |
| Jan 8, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -5,349 | $31.51 | $169k | 11,610 | Jan 8, 2026 |
| Jan 6, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,020 | $0.00 | $0 | 3,480 | Jan 8, 2026 |
| Jan 6, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,033 | $0.00 | $0 | 41,095 | Jan 8, 2026 |
| Jan 7, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,480 | $0.00 | $0 | 0 | Jan 8, 2026 |
| Jan 7, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -400 | $0.00 | $0 | 40,695 | Jan 8, 2026 |
| Jan 8, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,349 | $0.00 | $0 | 35,346 | Jan 8, 2026 |
Related signals
Other insiders at Revolve Group, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 65Notable | Revolve Group, Inc. | Michael Karanikolas CO-CHIEF EXECUTIVE OFFICER | $3.1M 119,241 shares | -196% | |
| 52Moderate | Revolve Group, Inc. | MMMK Development, Inc. owner | $3.1M 119,241 shares | -196% | |
| 65Notable | Revolve Group, Inc. | Michael Mente CO-CHIEF EXECUTIVE OFFICER | $3.1M 119,241 shares | -196% | |
| 56Moderate | Revolve Group, Inc. | Michael Karanikolas CO-CHIEF EXECUTIVE OFFICER | $414k 15,972 shares | -100% | |
| 43Moderate | Revolve Group, Inc. | MMMK Development, Inc. owner | $414k 15,972 shares | -100% | |
| 56Moderate | Revolve Group, Inc. | Michael Mente CO-CHIEF EXECUTIVE OFFICER | $414k 15,972 shares | -100% | |
| 57Moderate | Revolve Group, Inc. | Michael Karanikolas CO-CHIEF EXECUTIVE OFFICER | $459k 17,593 shares | -112% | |
| 44Moderate | Revolve Group, Inc. | MMMK Development, Inc. owner | $459k 17,593 shares | -112% | |
| 57Moderate | Revolve Group, Inc. | Michael Mente CO-CHIEF EXECUTIVE OFFICER | $459k 17,593 shares | -112% | |
| 65Notable | Revolve Group, Inc. | Michael Karanikolas CO-CHIEF EXECUTIVE OFFICER | $4.0M 139,010 shares | -425% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.